Loqtorzi significantly improved progression-free and overall survival in HER2-expressing advanced urothelial carcinoma compared to chemotherapy. The study demonstrated a higher overall response rate ...
First-line treatment with disitamab vedotin and toripalimab improved outcomes over chemotherapy in patients with HER2-expressing, locally advanced or metastatic urothelial carcinoma.
FX-909, a first-in-class investigational oral small molecule inhibitor of peroxisome proliferator-activated receptor gamma ...
Medpage Today on MSN
First-Line Bladder Cancer Trial Makes the Case for HER2 Screening
The first iteration of HER2-targeted drugs showed limited activity in bladder cancer, but the rise of antibody-drug ...
Initial results from one sub-study of the TROPION-PanTumor03 phase 2 trial showed that DATROWAY® (datopotamab deruxtecan) ...
Congress, a Phase III clinical study on disitamab vedotin plus toripalimab versus chemotherapy as first-line treatment for HER2-expressing locally advanced or metastatic urothelial carcinoma ...
Specific to patients with muscle invasive bladder cancer, improvement in disease free survival was also observed with ...
HER-2 targeted antibody-drug conjugate monotherapy has demonstrated efficacy in the post-chemotherapy setting for ...
The 2025 edition of the European Society for Medical Oncology(ESMO) was held this week in Berlin, delve into its key ...
Founded by Dr. Thomas Crisman, Genome Based Diagnostics has focused on developing accessible and reliable testing solutions ...
The study results reflect the effect of surgery with lymph node dissection alone in patients with high-grade invasive bladder cancer.
Over the past decade, immunotherapy has fundamentally reshaped the therapeutic landscape for several urological cancers, this mostly involved urothelial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback